Phase 1/2 Oncology Deal Benchmarks
Market Analysis
Phase 1/2 oncology licensing deals carry a median total deal value of $1.3B, with upfront payments ranging from $83M to $240M. At this stage, deal structures are heavily milestone-weighted, reflecting the significant clinical risk ahead. The recommended split allocates 13% to upfront and 87% to milestones.
The oncology landscape at the phase 1/2 stage is characterized by high competitive intensity with numerous active programs and a rapidly evolving standard of care. Development milestones average $362M, regulatory milestones contribute $416M, and commercial milestones reach $329M. ADCs, bispecifics, and radiopharmaceuticals continue to drive premium valuations across solid and hematologic tumors.
Royalty rates for phase 1/2 oncology deals range from 10.7% to 17.1% at the base tier, with high-tier escalation to 21.1%. Earlier-stage royalties are at the lower end of industry ranges, reflecting higher clinical risk.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the average upfront payment for phase 1/2 oncology deals?
How are phase 1/2 oncology deal milestones structured?
What royalty rates are typical for phase 1/2 oncology licensing?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.